Physician profile
Jonathan N Chang
NPI 1285053686
$7,153.78
in general payments reported to CMS, 2019-2025
20 companies · $871 in 2025
The $871 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $469 · 2023: $5,025 · 2024: $547 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,876 · Food and Beverage: $2,053 · Education: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,875.78 |
| Food and Beverage | $2,053.19 |
| Education | $1,514.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,645.53 | 2023-2025 | Da Vinci Surgical System, Davinci Xi |
| Sumitomo Pharma America, INC. | $394.48 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $275.81 | 2022-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $268.03 | 2021-2025 | |
| Pfizer INC. | $209.49 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $202.18 | 2022-2025 | |
| Organon LLC | $166.80 | 2021-2025 | Nexplanon |
| Biogen, INC. | $145.02 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $139.19 | 2021-2023 | Lo Loestrin Fe |
| Exeltis, USA INC. | $138.47 | 2022-2025 | Slynd |
| Evofem Biosciences, INC. | $99.99 | 2021-2022 | |
| Hologic Sales and Service, LLC | $97.12 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $90.82 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $58.10 | 2022-2023 | Gardasil 9 |
| Urovant Sciences INC | $55.79 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $45.27 | 2021 | |
| Minerva Surgical, INC | $32.84 | 2021-2023 | |
| Mylan Pharmaceuticals INC. | $32.82 | 2022 | |
| Scynexis, INC. | $32.34 | 2022 | |
| Dexcom, INC. | $23.69 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.